Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Hartford

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 22, 2019
Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902Daniel A Hamstra, Stephanie L Pugh, Herbert Lepor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 3, 2024
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926Douglas M Dahl, Joseph P Rodgers, William U Shipley, et al.
Journal of Neuro-Oncology|February 7, 2018
NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patientsArif N Ali, Peixin Zhang, W K Alfred Yung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observationBeryl McCormick, Kathryn Winter, Clifford Hudis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2021
Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804Beryl McCormick, Kathryn A Winter, Wendy Woodward, et al.
International Journal of Radiation Oncology, Biology, Physics|July 26, 2015
A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902Seth A Rosenthal, Daniel Hunt, A Oliver Sartor, et al.
European Urology Oncology|November 14, 2024
Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 TrialsKrishnan R Patel, Paul L Nguyen, James A Proudfoot, et al.
European Urology|January 29, 2023
Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised TrialLoren K Mell, Stephanie L Pugh, Christopher U Jones, et al.
International Journal of Radiation Oncology, Biology, Physics|January 3, 2023
Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized TrialsPaul L Nguyen, Huei-Chung Rebecca Huang, Daniel E Spratt, et al.
International Journal of Radiation Oncology, Biology, Physics|September 4, 2021
Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical TrialChristopher U Jones, Stephanie L Pugh, Howard M Sandler, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 22, 2019
Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902Daniel A Hamstra, Stephanie L Pugh, Herbert Lepor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 3, 2024
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926Douglas M Dahl, Joseph P Rodgers, William U Shipley, et al.
Journal of Neuro-Oncology|February 7, 2018
NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patientsArif N Ali, Peixin Zhang, W K Alfred Yung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observationBeryl McCormick, Kathryn Winter, Clifford Hudis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2021
Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804Beryl McCormick, Kathryn A Winter, Wendy Woodward, et al.
International Journal of Radiation Oncology, Biology, Physics|July 26, 2015
A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902Seth A Rosenthal, Daniel Hunt, A Oliver Sartor, et al.
European Urology Oncology|November 14, 2024
Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 TrialsKrishnan R Patel, Paul L Nguyen, James A Proudfoot, et al.
European Urology|January 29, 2023
Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised TrialLoren K Mell, Stephanie L Pugh, Christopher U Jones, et al.
International Journal of Radiation Oncology, Biology, Physics|January 3, 2023
Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized TrialsPaul L Nguyen, Huei-Chung Rebecca Huang, Daniel E Spratt, et al.
International Journal of Radiation Oncology, Biology, Physics|September 4, 2021
Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical TrialChristopher U Jones, Stephanie L Pugh, Howard M Sandler, et al.
Pageof 6